e-learning
resources
Virtual 2020
Pre-Congress Content
Multidrug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pulmonary surfactant: a Trojan Horse to deliver anti-TB drugs
A. Hidalgo (Saarbrücken, Germany), J. Perez-Gil (Madrid, Spain), C. Lehr (Saarbrücken, Germany)
Source:
Virtual Congress 2020 – Multidrug-resistant tuberculosis
Session:
Multidrug-resistant tuberculosis
Session type:
E-poster session
Number:
465
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Hidalgo (Saarbrücken, Germany), J. Perez-Gil (Madrid, Spain), C. Lehr (Saarbrücken, Germany). Pulmonary surfactant: a Trojan Horse to deliver anti-TB drugs. 465
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions?
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance
Source: Eur Respir J 2012; 39: 802-804
Year: 2012
Development of new drug products for inhalation therapy of tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 652s
Year: 2004
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Drug loaded liposomes of mesalamine incorporated into disease responsive microgels (Micro) for treating allergic asthma: An approach using smart drug delivery system
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015
Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
Evaluation of antituberculous drugs administration
Source: Eur Respir J 2002; 20: Suppl. 38, 547s
Year: 2002
Effect of antituberculosis treatment on cardiopulmonary responses to exercise in pulmonary tuberculosis
Source: International Congress 2016 – Clinical exercise physiology in health and disease
Year: 2016
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020
Year: 2020
Therapeutic strategies in pneumonia: going beyond antibiotics
Source: Eur Respir Rev 2015; 24: 516-524
Year: 2015
Response of pulmonary tuberculoma to anti-tuberculosis treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 521s
Year: 2003
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017
Year: 2018
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017
Year: 2018
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Availability of anti-tuberculosis drugs in Europe
Source: Eur Respir J 2012; 40: 500-503
Year: 2012
Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity
Source: International Congress 2014 – Tuberculosis: diagnosis
Year: 2014
Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Treatment of patients with extensive TB and concomitant bronchial lesions with some anti-TB drugs delivered via nebulizer
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013
Inhaled antibiotics: a new tool?
Source: Annual Congress 2009 - Antibiotics and the lung
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept